Inhibition of experimental proliferative vitreoretinopathy with protein kinase C inhibitor (chelerythrine chloride) and melatonin

Basit Öğe Kaydı
dc.authoridTürköz, Yusuf/0000-0001-5401-0720
dc.authoridParlakpinar, Hakan/0000-0001-9497-3468
dc.authoridParlakpınar, Hakan/0000-0001-9497-3468
dc.authorwosidTürköz, Yusuf/ABG-7931-2020
dc.authorwosidParlakpinar, Hakan/V-6637-2019
dc.authorwosidParlakpınar, Hakan/T-6517-2018
dc.contributor.authorEr, H
dc.contributor.authorTurkoz, Y
dc.contributor.authorMizrak, B
dc.contributor.authorParlakpinar, H
dc.date.accessioned2024-08-04T20:15:08Z
dc.date.available2024-08-04T20:15:08Z
dc.date.issued2006
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To investigate whether a protein kinase C (PKC) inhibitor and melatonin prevent proliferative vitreoretinopathy (PVR). Methods: Twenty pigmented rabbits were used in this study. All rabbits except controls received an intravitreal injection of 0.15 ml (75,000 units) of platelet-rich plasma into their left eye. The animals were divided into four groups: group I was treated with intravitreal injection of 0.15 ml (100 mu mol/ ml) of PKC inhibitor ( chelerythrine chloride), group II received 1 ml (4 mg/kg) of intraperitoneal melatonin for 3 days, group III received nothing (blank group), and group IV (control group) received only 0.5 ml of 1% ethanol intraperitoneally for 3 days. Proliferative changes were graded in a masked fashion by indirect ophthalmoscopy for a 15-day follow-up period. The malondialdehyde (MDA), reduced glutathione (GSH) and total nitrite levels were measured in the itreous humor. Results: The grades of PVR were A and B in group I and II, treated with PKC inhibitor and melatonin, respectively. The PVR grade in the blank group was C-D. The mean MDA level in group I (4.2 +/- 0.9 mu mol/ l) was significantly lower than in the blank group (6.0 +/- 1.0 mu mol/ l; p < 0.05). The mean GSH level in group I (66.3 +/- 8.8 mu mol/ l) was not significantly different from that in the blank group (p > 0.05). The MDA and GSH levels in group II were 3.2 +/- 0.7 and 70.1 +/- 13.3 mu mol/ l, respectively. Both these levels were significantly different from those of the blank group (p < 0.05). The NO levels in both treatment groups were significantly lower than in the blank group (p < 0.001). Conclusion: These findings suggest an inhibitory effect of PKC inhibitor and melatonin on PVR. The inhibition of PVR development was associated with lower MDA and NO levels with higher GSH levels in the treatment groups. Copyright (c) 2006 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000089270
dc.identifier.endpage22en_US
dc.identifier.issn0030-3755
dc.identifier.issn1423-0267
dc.identifier.issue1en_US
dc.identifier.pmid16374044en_US
dc.identifier.scopus2-s2.0-29244482228en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage17en_US
dc.identifier.urihttps://doi.org/10.1159/000089270
dc.identifier.urihttps://hdl.handle.net/11616/94193
dc.identifier.volume220en_US
dc.identifier.wosWOS:000234170300004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOphthalmologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchelerythrine chlorideen_US
dc.subjectprotein kinase C inhibitoren_US
dc.subjectproliferative vitreoretinopathyen_US
dc.subjectmelatoninen_US
dc.titleInhibition of experimental proliferative vitreoretinopathy with protein kinase C inhibitor (chelerythrine chloride) and melatoninen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu